Τόμος 27 (2009) – Τεύχος 1 – Άρθρο 20 – Επιθεώρηση Κλινικής Φαρμακολογίας και Φαρμακοκινητικής-Ελληνική Έκδοση – Volume 27 (2009) – Issue 1– Article 20 – Epitheorese Klinikes Farmakologias και Farmakokinetikes-Greek Edition

Μαρία Μυρωνίδου-Τζουβελέκη και Στέργιος Τσαρτσάλης

Α’ Εργαστήριο Φαρμακολογίας, Ιατρική Σχολή, Αριστοτέλειο Πανεπιστήμιο, Θεσσαλονίκη, Ελλάδα

Maria Mironidou-Tzouveleki and Stergios Tsartsalis

A’ Laboratory of Pharmacology, Medical School, Aristotle University, Thessaloniki, Hellas

2. Horowski R., Horowski L., Vogel S., Poewe W., Kielhorm F.-W.: An essay on Wilhelm von Humbolt and the shaking palsy. Neurology 45: 565-568 (1995)

3. Ropper A., Brown R.: Parkinson’s Disease. In: Adam’s and Victor’s Principles of Neurology. 8th Ed., pp. 915-925, McGraw Hill, 2005

4. McAuley J.: The physiological basis of clinical deficits in Parkinson’s disease. Prog. Neurobiol. 69: 27-48 (2003)

5. Guyton A, Hall J.: Basal ganglia-their motor functions. In: Textbook of Medical Physiology. 11th Ed., pp. 707-711, Elsevier Saunders, 2006

6. Galvan A., Wichmann T.: Pathophysiology of Parkinsonism. Clin. Neurophysiol. In Press (2008)

7. Purves D., Augustine G., Fitzpatrick D., Hall W., La Mantia A.-S., McNamara J., Williams S.M.: Modulation of movement by the basal ganglia. In: Neuroscience. 3rd Ed., pp. 417-433, Sinauer Associates Inc, 2004

8. Jung T., Grune T.: The proteasome and its role in the degradation of oxidized proteins. IUBMB Life 60: 743-752 (2008)

9. McNaught K., Olanow W.: Proteolytic stress: a unifying concept for the etiopathogenesis of Parkinson’s Disease. Ann. Neurol. 53(Suppl 3): S73-S84 (2003)

10. Konstantinova I.M., Tsimokha A.S., Mittenberg A.G.: Role of proteasomes in cellular regulation. Int. Rev. Cell Mol. Biol. 267: 59-124 (2008)

11. Lim K.-L., Tan J.: Role of the ubiquitin proteasome system in Parkinson’s disease. BMC Biochem. 8(Suppl 1): S13 (2007)

12. Olanow W., McNaught K.: Ubiquitin-proteasome system and Parkinson’s disease. Mov. Disord. 21: 1806-1823 (2006)

13. Belin A., Westerlund M.: Parkinson’s disease: a genetic perspective. FEBS J. 275: 1377-1383 (2008)

14. Schapira A., Cleeter M., Muddle J, Workman J., Cooper M., King R.: Proteasomal inhibition causes loss of nigral tyrosine hydroxylase neurons. Ann. Neurol. 60: 253-255 (2006)

15. Sun F., Anantharam V., Zhang D., Latchoumycandane C., Kanthasamy A., Kanthasamy A.: Proteasome inhibitor MG-132 induces dopaminergic degeneration in cell culture and animal models. Neurotoxicology 27: 807-815 (2006)

16. Wang X.-F., Li S., Chou A., Bronstein J.: Inhibitory effects of pesticides on proteasome activity: implication in Parkinson’s disease. Neurobiol. Dis. 23: 198-205 (2006)

17. Henn I., Bouman L., Schlehe J., Schlierf A., Schram J., Wegener E., Nakaso K., Culmsee C., Berninger B., Krappmann D., Tatzelt J., Winklholfer K.: Parkin mediates neuroprotection through activation of IκΒ Kinase/Nuclear Factor-κΒ signalling. J. Neurosci. 21: 1868-1878 (2007)

18. Tan E., Puong K., Chan D., Yew K., Fook-Chong S., Shen H., Ng P., Woo J., Yuen Y., Pavanni R., Wong M., Puvan K., Zhao Y.: Impaired transcriptional upregulation of Parkin promoter variant under oxidative stress and proteasomal inhibition: clinical association. Hum. Gen. 118: 484-488 (2005)

19. Gandhi S., Wood N.: Molecular pathogenesis of Parkinson’s disease. Hum. Mol. Gen. 14: 2749-55 (2005)

20. McNaught K., Belizaire R., Isacson O., Jenner P., Olanow W.: Altered proteasomal function in sporadic Parkinson’s disease. Exp. Neurol. 179: 38-46 (2003)

21. Peng Z., Chen M., Yap Y., Manikandan J., Melendez A., Choy M., Moore P., Cheung N.: Proteasome inhibition: an early or late event in nitric oxide-induced cell death? Nitric Oxide 18: 136-145 (2008)

22. Yoshimoto Y., Nakaso K., Nakashima K.: L-dopa and dopamine enhance the formation of aggregates under proteasome inhibition in PC12 cells. FEBS Lett. 579: 1197-1202 (2005)

23. Lee J., Wheeler T., Li L., Chin L.-S.: Ubiquitination of α-synuclein by Siah-1 promotes α-synuclein aggregation and apoptotic cell death. Hum. Mol. Gen. 17: 906-917 (2008)

24. Kyratzi E., Pavlaki M., Kontostavlaki D., Rideout H., Stefanis L.: Differential effects of parkin and its mutants on protein aggregation, the ubiquitin-proteasome system, and neuronal cell death in human neuroblastoma cells. J. Neurochem. 102: 1292-1303 (2007)

25. Snyder H., Mensah K., Theisler C., Lee J., Matouschek A., Wolozin B.: Aggregated and monomeric α-synuclein bin to the S6΄ proteasomal protein and inhibit proteasomal function. J. Biol. Chem. 278: 11753-11759 (2003)

26. Pan T., Kondo S., Zhu W., Xie W., Jankovich J., Le W.: Neuroprotection of rapamycin in lactacystin-induced neurodegeneration via aytophagy enhancement. Neurobiol. Dis. 32: 16-25 (2008)

27. Du Y., Li X., Yang D., Zhang X., Chen S., Huang K., Le W.: Multiple molecular pathways are involved in the neuroprotection of GDNF against proteasome inhibitor induced dopamine neuron degeneration in vivo. Exp. Biol. Med. (Maywood) 233: 881-890 (2008)

28. Naoi M., Maruyama W., Yi H., Akao Y., Yamaoka Y., Shamoto-Nagai M.: Neuroprotection by by propargylamines in Parkinson’s disease: intracellularmechanism underlying the anti-apoptotic function and search for clinical markers. J. Neural. Transm. Suppl. 72: 121-131 (2007)